Cell Therapeutics

Latest Headlines

Baxter and CTI BioPharma say they have come up with statistically significant topline data on the effectiveness and safety of pacritinib, their late-stage therapy for myelofibrosis. But after the biotech's many twists and turns taken trying to advance pixantrone over the years, a few longtime observers preferred to wait and see the actual numbers before deciding for themselves.

Cell Therapeutics got some good news from the FDA to start 2014. The agency has lifted a partial hold on tosedostat (IND 075503), giving the Seattle-based biotech a green light for all clinical studies of the cancer drug.

THE LIBRARY: WEBINAR

Pharma companies can employ several strategies for obtaining expedited approvals-including, in some cases, acquiring them from other companies. This webinar will feature regulatory experts from the pharma industry who can provide tips on navigating these programs. Register Today!